Key2Brain
Key2Brain AB is a Swedish preclinical biotech developing a proprietary blood-brain barrier-crossing VHH antibody platform that delivers CNS therapeutics to pharmaceutical partners via worldwide licensing and collaboration agreements.
- Company typePrivate
- Founded2020
- HeadquartersStockholm, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Key2Brain does
Key2Brain AB is a Swedish privately held biotechnology company founded in 2020 and headquartered at the Karolinska Institute Campus (Innomedicum, A Working Lab) in Solna, Stockholm. The company has developed a proprietary blood-brain barrier (BBB)-crossing platform technology based on small (<15 kDa) engineered single-domain VHH antibodies with monovalent specificity for the Transferrin Receptor (TfR). This modular platform is designed to be integrated with diverse therapeutic modalities — peptides, proteins, enzymes, monoclonal antibodies, and oligonucleotides — to enable efficient brain uptake and broad CNS distribution without disrupting disease target specificity.
Key2Brain operates a pure B2B licensing and collaboration business model. The company does not develop or commercialize its own therapeutic products; instead, it provides partners with worldwide, royalty-bearing licenses to combine its BBB shuttle technology with partner therapeutic candidates, while partners fund all research, development, and commercialization. Revenue streams take the form of upfront payments, development and sales-based milestones, and tiered royalties on potential sales, supplemented by collaborative research and option agreements. The customer base is concentrated among large pharmaceutical and specialty biotechnology companies — most notably Chiesi Group (Chiesi Global Rare Diseases) under a worldwide license for BBB-crossing enzyme replacement therapies in alpha-mannosidosis and Krabbe disease (June 2025), and OliX Pharmaceuticals under an evaluation and option agreement for CNS-targeted siRNA delivery (February 2026).
The company employs 1-10 staff, has received non-dilutive grant funding of up to SEK 4 million from VINNOVA (Sweden's Innovation Agency) under its Innovative Start-ups and Deeptech Acceleration programs, and reports no publicly disclosed equity financing. Its internal pipeline and partnered programs remain at the preclinical to early research stage.
Key2Brain firmographics
Firmographics- Name
- Key2Brain
- Legal name
- key2brain AB
- Website
- https://key2brain.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Key2Brain AB is a Swedish preclinical biotech developing a proprietary blood-brain barrier-crossing VHH antibody platform that delivers CNS therapeutics to pharmaceutical partners via worldwide licensing and collaboration agreements.
- Ownership category
- akta.pro rank
Key2Brain industry classification
Industry- Product category
- CNS Drug Delivery Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Key2Brain is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Key2Brain business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Licensing Revenue: Worldwide, royalty-bearing license agreements where Key2Brain provides technology access and receives upfront payments, development and sales-based milestone payments, and tiered royalties on potential sales. Partner funds all research, development, and subsequent commercialization worldwide.
- Collaborative Research Payments: Joint research agreements with option structures where Key2Brain conducts evaluation-based research alongside partners, with potential for future exclusive licensing rights upon successful technical validation.
Distribution channels2 records
Marketing channels3 records
Key2Brain product offering
Product offeringCore offering
Key2Brain develops and licenses a proprietary blood-brain barrier-crossing (BBB-crossing) platform technology based on small (<15 kDa) engineered single domain VHH antibodies that bind the Transferrin Receptor (TfR). The platform is modularly applied across peptides, proteins, enzymes, monoclonal antibodies, and oligonucleotides to enable efficient brain uptake and broad distribution of CNS therapeutics, and is commercialized through worldwide, royalty-bearing license agreements and collaborative research partnerships with pharmaceutical and biotechnology companies.
Product overview
Key2Brain is a Swedish biotechnology company developing next-generation brain targeting therapeutics using its proprietary blood-brain barrier-crossing (BBB-crossing) platform technology. The platform consists of small (<15 kDa) engineered single domain VHH antibodies targeting the Transferrin Receptor (TfR), which can be integrated with various therapeutic modalities including peptides, proteins, enzymes, mAbs, and oligonucleotides. The company's pipeline programs include the aMann-K2B program for alpha-mannosidosis and BBB-crossing ERT programs for Krabbe disease, developed both internally and through partnerships with Chiesi Group and OliX Pharmaceuticals.
Differentiator
Problem solved
Functional benefit
Products and services
- BBB-Crossing Platform Technology Proprietary blood-brain barrier-crossing technology based on small (<15 kDa) engineered single domain VHH antibodies with monovalent specificity for the Transferrin Receptor (TfR), enabling efficient brain uptake and broad distribution of CNS therapeutics across peptides, proteins, enzymes, mAbs, and oligonucleotides. Licensed to pharmaceutical and biotechnology partners for use in their therapeutic candidates.
- aMann-K2B Program Blood-brain barrier-crossing recombinant enzyme replacement therapy program for alpha-mannosidosis, developed in collaboration with Chiesi Global Rare Diseases under a worldwide licensing agreement.
- Krabbe Disease BBB-Crossing ERT
Quantifiable outcome
- Demonstrated efficient brain uptake and target engagement in preclinical models
Companies that use Key2Brain
Customer profileSegments3 records
Ideal customer profiles3 records
Key2Brain technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Key2Brain partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- OliX PharmaceuticalscoreStrategic evaluation and option agreement to develop CNS-targeted siRNA therapeutics using Key2Brain's TfR-targeted BBB shuttle technology. Joint research to assess CNS delivery efficiency and technical suitability. OliX may exercise option for worldwide exclusive license for conjugates incorporating OliX siRNA candidate with Key2Brain's TfR-targeting platform for undisclosed CNS target. Marks Key2Brain's first siRNA collaboration, highlighting platform versatility.
- Chiesi Group (Chiesi Global Rare Diseases)coreWorldwide licensing agreement to advance two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders including alpha-mannosidosis (aMann) and Krabbe disease (KD). Built on partnership initiated in 2022. Key2Brain receives upfront payment, development and sales-based milestone payments, and tiered royalties. Chiesi funds all research, development, and commercialization worldwide. Agreement includes framework to add additional enzymes to collaboration.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Key2Brain competitors and assessment
Company assessmentEmerging players
- Arma Biosciences: Early-stage biotech developing TfR-based BBB shuttle technology for CNS drug delivery; an emerging player pursuing the same receptor-mediated delivery strategy as Key2Brain.
- Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company developing CNS-targeted ASOs and siRNAs; relevant emerging player with overlap to Key2Brain's oligonucleotide delivery focus.
- Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based CNS delivery platforms for neurological diseases; comparable as a non-BBB-shuttle but emerging platform approach to delivering therapeutics to the brain.
Direct peers
- Denali Therapeutics: Clinical-stage US biotech developing engineered protein transport vehicles (TVs) targeting TfR1 to deliver therapeutics across the BBB - the most direct competitor to Key2Brain's VHH/TfR shuttle approach. Both companies pursue partner-funded CNS delivery platforms.
- JCR Pharmaceuticals: Japanese biopharma with its J-Brain Cargo BBB-penetrating antibody platform used to deliver enzyme replacement therapies across the BBB, including for lysosomal storage disorders - directly comparable to Key2Brain's Chiesi-partnered ERT programs.
- Vect-Horus: French biotech whose BBB-shuttle vector platform delivers small molecules, peptides, proteins, and nucleic acids across the BBB via receptor-mediated transport - directly comparable modular shuttle technology to Key2Brain's VHH/TfR platform.
- BioArctic: Swedish biotech developing CNS-targeted biologics (including brain-transport technologies for antibody delivery) with strong ties to the Karolinska ecosystem; a regional Swedish peer with overlapping BBB delivery and CNS focus.
Broad incumbents
- Roche / Genentech: Large incumbent running the Brainshuttle (TfR-based) program with various partners, including in CNS; broader portfolio but overlapping BBB-crossing platform ambition and deep CNS development capability.
- Ionis Pharmaceuticals: Established antisense oligonucleotide company with multiple CNS programs (e.g., ASOs for SMA, Huntington's); adjacent to Key2Brain because OliX/Key2Brain siRNA work overlaps with the oligonucleotide CNS delivery space.
- Alnylam Pharmaceuticals: Global leader in RNAi therapeutics with growing CNS siRNA pipeline (incl. partnerships to enable brain delivery); comparable to Key2Brain's OliX siRNA BBB shuttle work as a large incumbent pushing into CNS RNAi.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Key2Brain social profiles
Digital presenceKey2Brain financial estimates
Financial estimateRevenue estimate
Valuation estimate
Key2Brain leadership team
Management profileNumber of profiles
Profiles9 records
Key2Brain funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Key2Brain M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Key2Brain
What does Key2Brain do?
Key2Brain develops and licenses a proprietary blood-brain barrier-crossing (BBB-crossing) platform technology based on small (<15 kDa) engineered single domain VHH antibodies that bind the Transferrin Receptor (TfR). The platform is modularly applied across peptides, proteins, enzymes, monoclonal antibodies, and oligonucleotides to enable efficient brain uptake and broad distribution of CNS therapeutics, and is commercialized through worldwide, royalty-bearing license agreements and collaborative research partnerships with pharmaceutical and biotechnology companies.
Is Key2Brain a public or private company?
Key2Brain is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Key2Brain founded?
Key2Brain was founded in 2020. It employs 1 to 10 people.
Where is Key2Brain based?
Key2Brain is headquartered in Stockholm, Sweden, in the Europe region.
How does Key2Brain make money?
Two revenue lines are on record. Licensing Revenue is the primary driver. The others are collaborative Research Payments.
Who are Key2Brain's main competitors?
Emerging players on record are Arma Biosciences, Wave Life Sciences and Voyager Therapeutics. Direct peers are Denali Therapeutics, JCR Pharmaceuticals, Vect-Horus and BioArctic. Broad incumbents are Roche / Genentech, Ionis Pharmaceuticals and Alnylam Pharmaceuticals.
Does Key2Brain have an API?
No public API is recorded for Key2Brain.
What industry is Key2Brain in?
Key2Brain's product category is CNS Drug Delivery Technology. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.